穿支动脉粥样硬化病静脉溶栓后发生早期神经功能恶化的危险因素分析

doi:10.3760/cma.j.issn.1007-1245.2024.17.019

摘要/Abstract

摘要：

目的　探讨穿支动脉粥样硬化病（BAD）行阿替普酶静脉溶栓后发生早期神经功能恶化（END）的危险因素。方法　回顾性选取2021年1月至2023年1月于咸阳市中心医院神经内科住院并接受阿替普酶静脉溶栓治疗的急性脑梗死患者639例。静脉溶栓后行颅脑磁共振弥散加权成像+磁共振血管造影，证实为新发脑梗死，根据中国缺血性脑卒中分型标准筛选符合BAD的患者162例，年龄（63.71±11.44）岁，男112例（69.1%）、女50例（30.9%）。根据静脉溶栓治疗72 h内是否出现END分为END组（28例）及非进展组（134例）。组间比较采用独立样本t检验、χ²检验或Fisher确切概率法、Mann-Whitney U检验，采用单因素和二元logistic回归分析阿替普酶静脉溶栓治疗BAD发生END的危险因素。结果　单因素结果显示，END组患者溶栓前的美国国立卫生院卒中量表（NIHSS）评分、中重度卒中（NIHSS评分5～21分）、入院时收缩压、到院-溶栓时间（DNT）及中重度白质疏松程度均高于非进展组（均P<0.05）。进一步二元logistic回归分析显示，溶栓前NIHSS评分（OR=5.947，95%CI 2.822～46.775，P=0.020）、中重度白质疏松程度（OR=3.162，95%CI 1.272～22.357，P=0.034）是阿替普酶静脉溶栓后BAD患者发生END的独立危险因素。结论　溶栓前NIHSS评分、中重度白质疏松程度为BAD行阿替普酶静脉溶栓后发生END的独立危险因素。

关键词:

穿支动脉粥样硬化病, 静脉溶栓, 阿替普酶, 早期神经功能恶化, 危险因素

Abstract:

Objective　To explore the risk factors of early neurological deterioration in patients with perforating artery atherosclerosis treated by intravenous thrombolysis with alteplase. Methods　A retrospective study was conducted on 639 patients with acute cerebral infarction who were hospitalized in Department of Neurology, Xianyang Central Hospital from January 2021 to January 2023 and received intravenous thrombolysis with ateplase. After intravenous thrombolysis, magnetic resonance diffusion-weighted imaging and angiography were completed, confirming the diagnosis of newly diagnosed cerebral infarction. According to the Chinese ischemic stroke subclassification (CISS) classification criteria, 162 patients who met BAD were selected, including 112 males (69.1%) and 50 females (30.9%); they were (63.71±11.44) years old. According to whether the patient experienced early neurological deterioration (END) within 72 hours of intravenous thrombolysis with ateplase, they were divided into an END group (28 cases) and a non-progression group (134 cases). The data were compared between the two groups by independent-sample t test, χ² test, or Fisher's precision probability test, and Mann-Whitney U test. Single factor analysis and multivariate logistic regression analysis were used to identify the risk factors of early neurological deterioration in the patients with perforating artery atherosclerosis treated by intravenous thrombolysis with ateplase. Results　The univariate analysis showed that the score of National Institute of Health Stroke Scale (NIHSS) before thrombolysis, moderate to severe stroke (NIHSS score 5-21), systolic blood pressure at admission, door-to-needle time (DNT), and moderate to severe white matter osteoporosis in the END group were higher than those in the non-progression group (all P<0.05). Further multivariate logistic regression analysis showed that the score of NIHSS before thrombolysis (OR=5.947, 95%CI 2.822-46.775, P=0.020) and moderate to severe white matter osteoporosis (OR=3.162, 95%CI 1.272-22.357, P=0.034) were risk factors for BAD in the patients. Conclusion　NIHSS score before thrombolysis and degree of moderate to severe white matter osteoporosis are risk factors for END in patients with perforating artery atherosclerosis treated by intravenous thrombolysis with alteplase.

Key words:

Perforating artery atherosclerosis, Intravenous thrombolysis, Alteplase, Early neurological deterioration, Risk factors

王文娟王世峰陈鹏曹雪.

穿支动脉粥样硬化病静脉溶栓后发生早期神经功能恶化的危险因素分析 [J]. 国际医药卫生导报, 2024, 30(17): 2916-2921.

Wang Wenjuan, Wang Shifeng, Chen Peng, Cao Xue.

Analysis of risk factors for early neurological deterioration in patients with perforating artery atherosclerosis treated by intravenous thrombolysis with ateplase [J]. International Medicine and Health Guidance News, 2024, 30(17): 2916-2921.

参考文献

[1] 门雪娇,陈玮琪,许玉园,等. 穿支动脉粥样硬化病中国专家共识[J]. 中国卒中杂志,2021,16(5):508-514. DOI:10.3969/j.issn.1673-5765.2021.05.016.
[2] Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept[J]. Neurology, 1989,39(9):1246-1250. DOI: 10.1212/wnl.39.9.1246.
[3] Jang SH, Park SW, Kwon DH, et al. The length of an infarcted lesion along the perforating artery predicts neurological deterioration in single subcortical infarction without any relevant artery stenosis[J]. Front Neurol, 2020,11:553326. DOI: 10.3389/fneur.2020.553326.
[4] 管慧,李军成,冯念斌,等. 探讨阿司匹林联合他汀类药物治疗脑血栓的疗效及其对动脉斑块的影响[J]. 微量元素与健康研究,2019,36(1):82-83.
[5] Kohno N, Okada K, Yamagata S, et al. Distinctive patterns of three-dimensional arterial spin-labeled perfusion magnetic resonance imaging in subtypes of acute ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2016,25(7):1807-1812. DOI: 10.1016/j.jstrokecerebrovasdis. 2016.03.035.
[6] 吴川杰,吉训明. 急性缺血性卒中再灌注治疗研究年度进展2022[J]. 中华医学杂志,2023,103(11):858-862. DOI:10.3760/cma.j.cn112137-20221220-02679.
[7] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志,2018,51(9):666-682. DOI:10.3760/cma.j.issn.1006-7876.2018.09.004.
[8] Fazekas F, Schmidt R, Kleinert R, et al. The spectrum of age-associated brain abnormalities: their measurement and histopathological correlates[J]. J Neural Transm Suppl, 1998;53:31-39. DOI: 10.1007/978-3-7091-6467-9_4.
[9] Petrone L, Nannoni S, Del Bene A, et al. Branch atheromatous disease: a clinically meaningful, yet unproven concept[J]. Cerebrovasc Dis, 2016,41(1-2):87-95. DOI: 10.1159/000442577.
[10] Uchiyama S, Toyoda K, Kitagawa K, et al. Branch atheromatous disease diagnosed as embolic stroke of undetermined source: a sub-analysis of NAVIGATE ESUS[J]. Int J Stroke, 2019,14(9):915-922. DOI: 10.1177/1747493019852177.
[11] 吴磊,胡东,高续,等. CT灌注成像联合CT血管造影对急性前循环脑梗死患者发生早期神经功能恶化的预测价值[J]. 实用心脑肺血管病杂志,2022,30(12):106-109. DOI:10.12114/j.issn.1008-5971.2022.00.298.
[12] Wu X, Liu Y, Nie C, et al. Efficacy and safety of intravenous thrombolysis on acute branch atheromatous disease: a retrospective case-control study[J]. Front Neurol, 2020,11:581. DOI: 10.3389/fneur.2020.00581.
[13] Li W, Wu Y, Li XS, et al. Intravenous tirofiban therapy for patients with capsular warning syndrome[J]. Stroke Vasc Neurol, 2019,4(1):22-27. DOI: 10.1136/svn-2018-000163.
[14] 张文静,郭德刚,李博,等. 阿替普酶静脉溶栓后机械取栓对动脉粥样硬化性脑梗死患者神经功能及炎性反应的影响[J]. 国际医药卫生导报,2022,28(19):2677-2682. DOI:10.3760/cma.j.issn.1007-1245.2022.19.003.
[15] 王朝刚,张晓曼,李兆妍,等. 弥散加权成像和灌注加权成像在超急性期脑梗死诊断及预后评估中的应用价值[J]. 实用心脑肺血管病杂志,2022,30(12):100-105. DOI:10.12114/j.issn.1008-5971.2022.00.318.
[16] Feekes JA, Hsu SW, Chaloupka JC, et al. Tertiary microvascular territories define lacunar infarcts in the basal ganglia[J]. Ann Neurol, 2005,58(1):18-30. DOI: 10.1002/ana.20505.
[17] 孙龙胤. r-tPA静脉溶栓后追加巴曲酶治疗急性脑梗死的疗效观察[J/CD]. 世界最新医学信息文摘(连续型电子期刊),2020,20(20):132,134. DOI:10.3969/j.issn. 1671-3141.2020.20.082.
[18] 邹兴菊,谢雪梅,赵雪,等. 替罗非班治疗经阿替普酶静脉溶栓治疗后神经功能恶化的穿支动脉梗死患者的疗效及安全性研究[J]. 实用心脑肺血管病杂志,2020,28(11):42-47. DOI:10.3969/j.issn.1008-5971.2020.11.008.
[19] Park MG, Oh EH, Kim BK, et al. Intravenous tissue plasminogen activator in acute branch atheromatous disease: does it prevent early neurological deterioration?[J]. J Clin Neurosci, 2016,33:194-197. DOI: 10.1016/j.jocn.2016.04.011.
[20] 朱大猛. 老年急性穿支动脉型脑梗死患者应用替罗非班治疗的临床效果观察[J]. 中国现代药物应用,2022,16(5):92-94. DOI:10.14164/j.cnki.cn11-5581/r.2022.05.033.
[21] Wei H, Wang Y, Zhang Y, et al. Outcomes and risk factors of perforating and non-perforating middle cerebral artery infarctions after intravenous thrombolysis[J]. J Thromb Thrombolysis, 2022,53(3):722-730. DOI: 10.1007/s11239-021-02620-2.
[22] 夏旺旭,张明,何永芳,等. 缺血性脑卒中患者预后不良的影响因素及其风险预测列线图模型构建[J]. 实用心脑肺血管病杂志,2022,30(10):51-56. DOI:10.12114/j.issn. 1008-5971.2022.00.239.
[23] 刘文灿,叶斌,汪敬业,等. 血清D-二聚体水平和溶栓前NIHSS评分对急性缺血性脑卒中患者rt-PA静脉溶栓后早期神经功能恢复的预测价值[J]. 淮海医药,2023,41(4):365-369. DOI:10.14126/j.cnki.1008-7044.2023.04.008.
[24] Chen Y, Yan S, Xu M, et al. More extensive white matter hyperintensity is linked with higher risk of remote intracerebral hemorrhage after intravenous thrombolysis[J]. Eur J Neurol, 2018,25(2):380-e15. DOI: 10.1111/ene.13517.
[25] 李莹. 中重度脑白质疏松对急性脑梗死静脉溶栓患者出血转化及预后的影响[J]. 农垦医学,2020,42(6):501-503. DOI:10.3969/j.issn.1008-1127.2020.06.005.
[26] 赵丽姣,杨松海,陈善鹏,等. 老年急性脑梗死患者阿替普酶静脉溶栓后疗效观察及相关因素分析[J]. 脑与神经疾病杂志,2023,31(3):180-185.
[27] Griessenauer CJ, McPherson D, Berger A, et al. Effects of white matter hyperintensities on 90-day functional outcome after large vessel and non-large vessel stroke[J]. Cerebrovasc Dis, 2020,49(4):419-426. DOI: 10.1159/000509071.
[28] Fisher CM. Lacunar strokes and infarcts: a review[J]. Neurology, 1982,32(8):871-876. DOI: 10.1212/wnl. 32.8.871.
[29] 陈桂林,钱云,陆小伟. 老年人肾功能损伤与脑白质高信号和扩大的血管周围间隙的关系[J]. 临床神经病学杂志,2019,32(2):95-98. DOI:10.3969/j.issn.1004-1648.2019. 02.009.
[30] Frey BM, Petersen M, Schlemm E, et al. White matter integrity and structural brain network topology in cerebral small vessel disease: the Hamburg city health study[J]. Hum Brain Mapp, 2021,42(5):1406-1415. DOI: 10.1002/hbm.25301.
[31] Zhang CE, Wong SM, van de Haar HJ, et al. Blood-brain barrier leakage is more widespread in patients with cerebral small vessel disease[J]. Neurology, 2017,88(5):426-432. DOI: 10.1212/WNL.0000000000003556.